Silver Book reference

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

1 Matching Fact

Search matching Facts:
No results to display
    • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…